John Crowley, CEO of the Biotechnology Innovation Organization (Credit: BIO via website)
June 11, 2024 09:02 AM EDT
China
In Focus

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Andrew Dunn

Senior Biopharma Correspondent

Jared Whitlock

Features Editor

Max Bayer

Pharma Reporter

SAN DIEGO — Fac­ing an ex­is­ten­tial mo­ment in how drugs are de­vel­oped and sold, biotech’s key lob­by­ing group has en­trust­ed a new leader, who is wrap­ping …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times